Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

The success of weight-loss injections has prompted pharmaceutical companies to produce a next-generation anti-obesity pill

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for obesity and 23% being treated for diabetes after a year on the drugs, researchers reported Sept.

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

A study has found that despite its popularity, Ozempic isn’t actually the most effective weight loss drug out there. Ozempic, which was originally designed as a treatment for people with type 2 diabetes,

The ubiquity of Ozempic has heightened the debate over body positivity and the shaming of celebrities who use it to achieve dramatic results The post Hollywood Struggles With Ozempic Shame: Why Hardly Anyone Admits to Taking the Trendy Weight-Loss Drug appeared first on TheWrap.